Lexicon jumps on Phase II carcinoid syndrome data

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $0.30 (13%) to $2.69 on Friday after reporting data from a Phase II trial of telotristat etiprate to treat refractory carcinoid syndrome. The tryptophan hydroxylase inhibitor produced a significant median reduction of 46.4% in the number of bowel movements at week 12 compared to baseline, the primary efficacy endpoint (p<0.001). The open-label, dose-escalation, European trial enrolled 15 patients with metastatic carcinoid syndrome who were refractory or intolerable to somatostatin analog therapy. ...